drugset / Trial / NCT06972875

Fezolinetant for Treating Hot Flashes in Men With Prostate Cancer

NCT06972875

Phase 2 Recruiting 32 enrolled University of Vermont
NaSingle-groupOpen-labelTreatment

Summary

This study is for men with prostate cancer who are experiencing hot flashes due to treatments that lower testosterone. Hot flashes can affect your quality of life and make it harder for patients to continue their treatment, so researchers want to find a better way to manage them. The study is testing a drug called fezolinetant, which might help reduce hot flashes without using hormones. Fezolinetant is a drug that is currently approved for the treatment of hot flashes in menopausal women.

Timeline

Start
2025-12-18
Primary completion
2027-01
Completion
2027-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Fezolinetant Small molecule 45 mg Oral

Indications